BioNexus Gene Lab Corp.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Su-Leng Tan
- Full Time Employees
- 30
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- Tower B, Vertical Business Suite Kuala Lumpur Malaysia 59200
- IPO Date
- Jan 8, 2021
- CIK
- 0001737523
- Website
- bionexusgenelab.com
- Similar Companies
- Business
- BioNexus Gene Lab Corp. is a biotechnology company specializing in precision diagnostics and specialty chemical solutions with a focus on blood-based genomic screening (BGS) for early detection of diseases. The company develops and commercializes proprietary non-invasive liquid biopsy tests that analyze changes in ribonucleic acid (RNA) to detect susceptibility to common cancers, inflammatory diseases, and osteoarthritis before symptoms manifest. Its core products and services include blood-based genomic screening tests against eight common cancers and two inflammatory diseases, provision of chemical raw materials for industrial, medical, appliance, aerospace, automotive, mechanical, and electronic manufacturing in Southeast Asia, and investment holding activities. BioNexus operates through its wholly owned subsidiary MRNA Scientific Sdn. Bhd., which owns proprietary algorithm software and technology for disease detection through blood analysis. The company serves markets primarily in Malaysia, Indonesia, Vietnam, and other Southeast Asian countries. Founded in 2017 and headquartered in Kuala Lumpur, Malaysia, BioNexus also holds strategic investments and partnerships to expand its healthcare technology offerings. Recently, BioNexus completed a strategic investment in Fidelion Diagnostics, acquiring a 15% equity stake and securing exclusive, perpetual commercial rights for Fidelion’s VitaGuard™ Tumor-Naïve Minimal Residual Disease (MRD) liquid biopsy platform across the ASEAN region. This agreement positions BioNexus as the sole provider and manufacturer of advanced liquid biopsy technology in one of the fastest-growing precision oncology markets globally, enhancing its capability in non-invasive cancer diagnostics. Additionally, in 2024, the company made a significant investment of approximately USD 228,000 in Malaysian healthcare technology firm Ascension Innovation Sdn Bhd (AISB), aimed at integrating BioNexus's genomic screening expertise with AISB's AI-driven healthcare digital platforms to improve clinical management and patient care. These strategic moves mark BioNexus’s expansion into precision oncology and AI-powered healthcare solutions, reinforcing its presence in Southeast Asia’s evolving healthcare landscape.
BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-Development
BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform
BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman
Financial Comparison: Beauty Health (NASDAQ:SKIN) vs. BioNexus Gene Lab (NASDAQ:BGLC)
BioNexus Gene Lab (NASDAQ:BGLC) Stock Price Up 1.7% – Still a Buy?
BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN's Multi-Billion Dollar Market
BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for VitaGuard™
BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization
BioNexus Gene Lab Corp. (Nasdaq: BGLC) and Fidelion Diagnostics Execute Exclusive Southeast Asia License for VitaGuard™ MRD Platform as Part of Strategic Alliance with Tongshu Gene
BioNexus Gene Lab Corp. (Nasdaq: BGLC) Announces Strategic Agreements with Fidelion Diagnostics for Southeast Asia MRD Commercialization
BioNexus Gene Lab Corp. Files $100 Million Shelf Registration and Establishes $20 Million At-the-Market Program to Advance Strategic Growth Opportunities
PACS Group (NYSE:PACS) versus BioNexus Gene Lab (NASDAQ:BGLC) Critical Contrast
BioNexus Gene Lab Corp Signs Strategic Partnership Term Sheet with BirchBioMed Inc.
BioNexus Gene Lab Corp. and Fidelion Diagnostics Announce Landmark Alliance—Touted as a new “DeepSeek Moment” in Precision Oncology
BioNexus Gene Lab Corp. Regains Nasdaq Compliance, Signaling Strategic Stability and Growth Readiness
BioNexus Gene Lab Corp. Files 2024 Annual Report Highlighting Strategic Innovation, Operational Resilience, and Growth Trajectory
BioNexus Gene Lab Corp and ML Tech Partner to Enhance Ethereum-focused Treasury Strategy
BioNexus Gene Lab Corp. Announces Board Approval of Ethereum Treasury Strategy and Release of Strategic Whitepaper
BioNexus Gene Lab Corporation announces entry into Biogas Sector via Teaming Agreement with Protech Builders Sdn. Bhd.
BioNexus Gene Lab Corp. Signs Strategic Outsourcing Agreement with VITARRAY Global Pte. Ltd.